The party says the 62-day waiting times standard has not been met since 2012. They said if they win the Scottish elections in ...

Rishi Sunak is renewing calls for a 'vital' national prostate cancer-screening programme as he prepares to attend a testing open day.

The Government now has the chance to save countless lives by introducing a targeted screening programme for prostate cancer , the most common cancer among British men.

After exciting clinical trial results, Bell Potter has maintained its rating on this exciting ASX healthcare stock.

Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, focusing on how contemporary therapeutic choices in metastatic hormone-sensitive ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts ...

Cardiovascular disease is the second leading cause of death among cancer survivors, second only to cancer itself. The same treatments that can save patients from cancer may also r ...

A former Rosyth dockyard worker has revealed the 'horrendous' experience of his prostate cancer to encourage men to get tested. Alex Keatings, 68, who worked for decades as a manager for the aircraft ...

A new international study has found that combining two cancer medicines may significantly slow the growth of a dangerous form of prostate cancer in some men. The research was led by scientists at ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...

Johnson & Johnson (NYSE: JNJ) is one of Goldman Sachs top healthcare stocks. On March 10, Johnson & Johnson (NYSE:JNJ) announced the submission of a Type II variation application to the European ...